Erythropoietin

(redirected from Erythropoietins)
Also found in: Dictionary, Thesaurus, Medical.
Related to Erythropoietins: Hemopoietin, erythropoietin stimulating factor

erythropoietin

[ə‚rith·rə′pȯi·ət·ən]
(biochemistry)
A hormone, thought to be produced by the kidneys, that regulates erythropoiesis, at least in higher vertebrates.

Erythropoietin

 

a hormone that stimulates the formation of erythrocytes in bone marrow. Characterized as a glycoprotein, erythropoietin has a carbohydrate content of 35 percent. It has a molecular weight of 30,000–40,000 and possesses antigenic properties. Erythropoietin is inactivated by neuraminidase, trypsin, chymotrypsin, and papain.

Erythropoietin was discovered by the French researchers F. Corneau and C. de Flandre in 1906 in rabbit serum that they tested after drawing blood. The hormone is found in low concentrations under normal physiological conditions, but the levels increase when the subject is in a state of hypoxia as a result of the loss of blood, a decrease in the oxygen content of the air, or various forms of anemia. Most scientists believe that erythropoietin is formed in the kidneys. When the hormone acts on stem cells in bone marrow, it causes their differentiation into cells of the erythroid series.

REFERENCES

Fedorov, N. A., and M. G. Kakhetelidze. Eritropoetin. Moscow, 1973.
Normal’noe krovetvorenie i ego reguliatsiia. Moscow, 1976.
Gordon, A. S. Regulation of Hematopoiesis, vol. 1. New York [1970].

N. A. FEDOROV

References in periodicals archive ?
Contract notice: Framework agreement erythropoietin.
Market Analysis III-51 Outlook III-51 India III-51 Biopharmaceutical Drugs Market: Promising Opportunities III-51 Erythropoietins III-52 G-CSF Market III-52 Interferons III-52 Strategic Corporate Developments III-53 Key Players III-53 B.
Market Analysis III-20 Outlook III-20 Erythropoietin Market III-20 Leading EPO Drugs in Japan III-20 HCV Infection: Combination Therapy Dominates III-20 Product Launches III-21 Chugai Pharmaceutical Co.
The report launched a flurry of investigations by the companies that make and market recombinant human erythropoietin.
Based on this, experts are now urging physicians to administer erythropoietin intravenously when feasible.
Recombinant human erythropoietin (rHuEPO) is a sialoglycoprotein hormone that appears to be immunologically and biologically equivalent to the endogenous compound, enhancing erythropoiesis dose-proportionally.
Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins
Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-65
Transgene Biotek to Sell Erythropoietin Product to Tss Export
Table 11: World Historic Review for Erythropoietins by
The erythropoiesis stimulating effects of erythropoietin
Amgen revolutionized anemia treatment with the development of a recombinant human erythropoietin, epoetin alfa, which is currently marketed in the U.